Anavex Life Sciences Corp (AVXL)

[falconer66a]

Anavex has several new drugs, beyond blarcamesine.

With long-lasting disease-modifying properties at low dose, AF710B [Anavex 3-71] is a promising novel therapeutic agent for treating Alzheimer's and other related diseases.

Those who haven't studied or are unaware of the several other molecules Anavex owns will focus only on blarcamesine (Anavex 2-73). But Anavex owns several other significant and promising sigma-1 receptor antagonists (activators). Right now, the most promising of these others is Anavex 3-71. All experimental evidence, in lab rodents (murines), shows that this molecule activates the sigma-1 protein at concentrations far lower than blarcamesine. In both humans and murines blarcamesine is administered in milligrams. Anavex 3-71 is dosed in micrograms. One milligram is a thousandth of gram. A microgram is a millionth of a gram.

The significance of that? First, per-dose manufacturing costs for Anavex 3-71 will be but a small fraction of those for blarcamesine. A decided economic benefit for the company. At the same time manufacturing costs can be lower but profit margins higher. Everyone will benefit.

But, of course, that will work only if Anavex 3-71 equals or exceeds blarcamesine's efficacies and safety. From the publicly-available murine studies it appears that this will be the case. Only proper clinical trials in humans will decide the matter. Very likely, as soon as Anavex has a revenue stream, human trials with Anavex 3-71 will commence.

Very likely, blarcamesine will be the first Anavex drug to get FDA approval, for any one of these debilities: Rett syndrome, Parkinson's disease dementia, and/or Alzheimer's disease. But it's very likely that blarcamesine's clinical life will be short; after successful human trials it will be replaced with Anavex 3-71.

Anavex Life Sciences Corp is not a one-trick pony (or one-molecule biotech). The activation of the sigma-1 receptor protein, by either blarcamesine or Anavex 3-71, will treat or prevent a number of central nervous system diseases.

Anavex's CNS drug firepower is broad and strong. Let's see what happens in the next five years. Not a one-trick pony. The Anavex barn has a unique molecular herd of powerful new stallion-type drugs.